CDKN2A and neoplasm: Despite the clear advantages of a de novo tumor in an immunocompetent environment, the tumor remains a mouse tumor and not a human tumor—and these may act/react differently, e.g. CDKN2A/B is present at chromosome 9 in humans but chromosome 4 in mice [161, 162].